Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy

Anthony D. Yang, Todd W. Bauer, E. Ramsay Camp, Ray Somcio, Wenbiao Liu, Fan Fan, Lee M. Ellis

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

It is believed that impairments in delivery of antineoplastic agents to solid tumors result from abnormalities of the tumor microenvironment. Vascular endothelial growth factor (VEGF), the prototypical angiogenic molecule, is one of the main factors responsible for the development and maintenance of the aberrant tumor vascular network, which is characterized by chaotic, leaky blood vessels with high interstitial fluid pressure and inefficient blood flow. The authors proposed that anti-VEGF therapy would reduce the elevated interstitial fluid pressure in tumors, thereby improving blood flow and potentially improving delivery of cytotoxic agents to tumor cells. For the current report, the authors reviewed characteristics of the abnormal tumor vasculature created under the influence of VEGF, the resulting tumor microenvironment, how the tumor microenvironment may impede delivery of antineoplastic agents, and how the combination of anti-VEGF and cytotoxic therapy may maximize the efficacy of antineoplastic treatment regimens.

Original languageEnglish (US)
Pages (from-to)1561-1570
Number of pages10
JournalCancer
Volume103
Issue number8
DOIs
StatePublished - Apr 15 2005
Externally publishedYes

Fingerprint

Antineoplastic Agents
Vascular Endothelial Growth Factor A
Tumor Microenvironment
Extracellular Fluid
Neoplasms
Blood Vessels
Therapeutics
Cytotoxins
Maintenance
Blood Pressure
Pressure

Keywords

  • Angiogenesis
  • Chemotherapy
  • Endothelial cell
  • Interstitial fluid pressure
  • Permeability
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Yang, A. D., Bauer, T. W., Camp, E. R., Somcio, R., Liu, W., Fan, F., & Ellis, L. M. (2005). Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy. Cancer, 103(8), 1561-1570. https://doi.org/10.1002/cncr.20942

Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy. / Yang, Anthony D.; Bauer, Todd W.; Camp, E. Ramsay; Somcio, Ray; Liu, Wenbiao; Fan, Fan; Ellis, Lee M.

In: Cancer, Vol. 103, No. 8, 15.04.2005, p. 1561-1570.

Research output: Contribution to journalArticle

Yang, AD, Bauer, TW, Camp, ER, Somcio, R, Liu, W, Fan, F & Ellis, LM 2005, 'Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy', Cancer, vol. 103, no. 8, pp. 1561-1570. https://doi.org/10.1002/cncr.20942
Yang AD, Bauer TW, Camp ER, Somcio R, Liu W, Fan F et al. Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy. Cancer. 2005 Apr 15;103(8):1561-1570. https://doi.org/10.1002/cncr.20942
Yang, Anthony D. ; Bauer, Todd W. ; Camp, E. Ramsay ; Somcio, Ray ; Liu, Wenbiao ; Fan, Fan ; Ellis, Lee M. / Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy. In: Cancer. 2005 ; Vol. 103, No. 8. pp. 1561-1570.
@article{37c5414f54704e6bbcc479da5c925731,
title = "Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy",
abstract = "It is believed that impairments in delivery of antineoplastic agents to solid tumors result from abnormalities of the tumor microenvironment. Vascular endothelial growth factor (VEGF), the prototypical angiogenic molecule, is one of the main factors responsible for the development and maintenance of the aberrant tumor vascular network, which is characterized by chaotic, leaky blood vessels with high interstitial fluid pressure and inefficient blood flow. The authors proposed that anti-VEGF therapy would reduce the elevated interstitial fluid pressure in tumors, thereby improving blood flow and potentially improving delivery of cytotoxic agents to tumor cells. For the current report, the authors reviewed characteristics of the abnormal tumor vasculature created under the influence of VEGF, the resulting tumor microenvironment, how the tumor microenvironment may impede delivery of antineoplastic agents, and how the combination of anti-VEGF and cytotoxic therapy may maximize the efficacy of antineoplastic treatment regimens.",
keywords = "Angiogenesis, Chemotherapy, Endothelial cell, Interstitial fluid pressure, Permeability, Vascular endothelial growth factor",
author = "Yang, {Anthony D.} and Bauer, {Todd W.} and Camp, {E. Ramsay} and Ray Somcio and Wenbiao Liu and Fan Fan and Ellis, {Lee M.}",
year = "2005",
month = "4",
day = "15",
doi = "10.1002/cncr.20942",
language = "English (US)",
volume = "103",
pages = "1561--1570",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy

AU - Yang, Anthony D.

AU - Bauer, Todd W.

AU - Camp, E. Ramsay

AU - Somcio, Ray

AU - Liu, Wenbiao

AU - Fan, Fan

AU - Ellis, Lee M.

PY - 2005/4/15

Y1 - 2005/4/15

N2 - It is believed that impairments in delivery of antineoplastic agents to solid tumors result from abnormalities of the tumor microenvironment. Vascular endothelial growth factor (VEGF), the prototypical angiogenic molecule, is one of the main factors responsible for the development and maintenance of the aberrant tumor vascular network, which is characterized by chaotic, leaky blood vessels with high interstitial fluid pressure and inefficient blood flow. The authors proposed that anti-VEGF therapy would reduce the elevated interstitial fluid pressure in tumors, thereby improving blood flow and potentially improving delivery of cytotoxic agents to tumor cells. For the current report, the authors reviewed characteristics of the abnormal tumor vasculature created under the influence of VEGF, the resulting tumor microenvironment, how the tumor microenvironment may impede delivery of antineoplastic agents, and how the combination of anti-VEGF and cytotoxic therapy may maximize the efficacy of antineoplastic treatment regimens.

AB - It is believed that impairments in delivery of antineoplastic agents to solid tumors result from abnormalities of the tumor microenvironment. Vascular endothelial growth factor (VEGF), the prototypical angiogenic molecule, is one of the main factors responsible for the development and maintenance of the aberrant tumor vascular network, which is characterized by chaotic, leaky blood vessels with high interstitial fluid pressure and inefficient blood flow. The authors proposed that anti-VEGF therapy would reduce the elevated interstitial fluid pressure in tumors, thereby improving blood flow and potentially improving delivery of cytotoxic agents to tumor cells. For the current report, the authors reviewed characteristics of the abnormal tumor vasculature created under the influence of VEGF, the resulting tumor microenvironment, how the tumor microenvironment may impede delivery of antineoplastic agents, and how the combination of anti-VEGF and cytotoxic therapy may maximize the efficacy of antineoplastic treatment regimens.

KW - Angiogenesis

KW - Chemotherapy

KW - Endothelial cell

KW - Interstitial fluid pressure

KW - Permeability

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=16844366291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16844366291&partnerID=8YFLogxK

U2 - 10.1002/cncr.20942

DO - 10.1002/cncr.20942

M3 - Article

C2 - 15754332

AN - SCOPUS:16844366291

VL - 103

SP - 1561

EP - 1570

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -